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Abstract 
Metastasis is one of the most important factors that lead to poor prognosis in cancer patients, and 
effective suppression of the growth of primary cancer cells in a metastatic site is paramount in averting 
cancer progression. However, there is a lack of biomimetic three-dimensional (3D) in vitro models that 
can closely mimic the continuous growth of metastatic cancer cells in an organ-specific extracellular 
microenvironment (ECM) for assessing effective therapeutic strategies. 
Methods: In this metastatic tumor progression model, kidney cancer cells (Caki-1) and hepatocytes (i.e., 
HepLL cells) were co-cultured at an increasing ratio from 1:9 to 9:1 in a decellularized liver matrix 
(DLM)/gelatin methacryloyl (GelMA)-based biomimetic liver microtissue in a microfluidic device. 
Results: Via this model, we successfully demonstrated a linear anti-cancer relationship between the 
concentration of anti-cancer drug 5-Fluorouracil (5-FU) and the percentage of Caki-1 cells in the 
co-culture system (R2 = 0.89). Furthermore, the Poly(lactide-co-glycolide) (PLGA)-poly(ethylene glycol) 
(PEG)-based delivery system showed superior efficacy to free 5-FU in killing Caki-1 cells. 
Conclusions: In this study, we present a novel 3D metastasis-on-a-chip model mimicking the 
progression of kidney cancer cells metastasized to the liver for predicting treatment efficacy. Taken 
together, our study proved that the tumor progression model based on metastasis-on-a-chip with 
organ-specific ECM would provide a valuable tool for rapidly assessing treatment regimens and 
developing new chemotherapeutic agents. 
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Introduction 
Although significant advances have been made 
to save cancer patients’ lives, metastasis is still the 
leading cause of cancer-related mortality, accounting 
for approximately 90% of global cancer deaths [1]. As 
reported, the 5-year survival rate of patients with a 
primary tumor is relatively high, whereas metastasis 
can considerably reduce the 5-year survival rate to 
less than 30% [1, 2]. Chemotherapy remains the 
mainstream treatment strategy for metastatic cancer, 
particularly when the primary tumor cannot be 
surgically removed [3, 4]. Although chemotherapy 
plays a key part in the plethora of options for the 
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clinical management of metastatic cancer, the success 
rate of developing effective chemo-compounds is less 
than 5% due to the limitation of conventional models 
[5]. The selection of highly effective anticancer 
treatment rather than empirical treatment is much 
needed for curbing cancer progression in metastatic 
cancer patients. It is, therefore, essential to identify 
effective anticancer chemotherapies and optimize 
drug delivery efficiency for improved clinical 
outcomes in metastatic cancer patients. 
Traditionally, two-dimensional (2D) cell cultures 
and animals have been used as primary tumor and 
metastatic cancer drug development models. 
Although 2D cell culture is relatively easy to perform, 
it lacks the essential physiopathological cues in the 
tumor microenvironment and metastatic niche [6, 7]. 
As such, the inadequacies of traditional 2D models lie 
in their inability to accurately simulate the complex, 
interact with appropriate physiopathological 
conditions or predict the in vivo effectiveness of 
anticancer compounds [8-10]. On the other hand, 
animal models for drug testing are labor/time 
intensive, costly, and most importantly, often yield 
untranslatable results due to the physiological 
differences between humans and animal models 
[11-14]. Therefore, the creation of cost-effective, 
reliable, and pragmatic in vitro models that can be 
used for accurately screening anticancer drug effects 
as well as overcoming the drawbacks of conventional 
models is of great importance for improving the 
current clinical management of primary tumor and 
metastatic cancer [15-18]. 
In recent years, organ-on-chip platforms, due to 
their 3D nature and cost-effectiveness, have been 
developed to model the metastatic cascade within 
conditioned microenvironments [19-23]. Metastasis- 
on-a-chip models have been used to study the 
metastatic cascade and offer a feasible platform for 
drug testing [24-26]. For instance, a metastasis- 
on-a-chip was constructed to mimic the migration of 
metastatic tumors from the intestine to the liver and to 
allow real-time tracking of cell movement and 
behavior [27]. However, this study only used 
hyaluronic acid hydrogel without considering 
organ-specific ECM in the migration model. In 
another study, normal breast cells are co-cultured 
with breast cancer cells to simulate cancer models at 
mild, moderate, and severe stages, in which cell 
density is found to be highly correlated with the 
incidence of metastasis [28]. However, this study used 
a 2D rather than a 3D model to investigate cancer 
migration and drug screening. Therefore, the 
progression of post-metastasis tumor within an 
organ-specific ECM has not been studied. 
In this article, we present a new 
metastasis-on-a-chip model incorporated with 
organ-specific ECM. This model can mimic the 
progression of kidney cancer cells in the liver to 
predict the therapeutic effects and evaluate dosage 
responses of anticancer drugs in a physiologically 
relevant liver microenvironment. We cultured kidney 
cancer cells (Caki-1) in a DLM/GelMA-based 3D 
biomimetic liver microtissue via continuous 
perfusion. Within this model, we co-cultured the 
Caki-1 and HepLL cells in increasing ratios from 1:9 to 
9:1 to investigate the progression of metastatic kidney 
cancer cells in the liver. We observed that there was a 
linear anticancer relationship between the 
concentration of 5-Fluorouracil (5-FU) and the 
percentage of Caki-1 cells in the metastatic tumor 
progression model, and that the 5-FU-loaded 
PLGA-PEG nanoparticles (NPs) showed a stronger 
killing efficacy than free 5-FU. Our findings 
demonstrate that the tumor progression model can be 
used to establish 3D metastatic cancer in vitro models 
and to rapidly assess anti-cancer efficiency and 
optimize dosage regimes. 
Methods 
Decellularization and characterization of DLM 
The decellularized scaffold of liver was prepared 
according to the method previously described [29]. 
The use of Sprague-Dawley rats and their livers was 
approved by the Zhejiang University Experimental 
Animal Welfare Ethics Committee (ZJU20170787). For 
scanning electron microscope (SEM) imaging, both 
the native livers and the DLM were frozen and 
maintained at -20 °C for 12 hours before 
lyophilization for 24 hours. The native livers and 
DLM were observed and analyzed with the aid of a 
SEM (Hitachi, Tokyo, Japan). 
The H&E and immunofluorescence staining 
were performed after sectioning native liver tissues 
and DLM. The sectioned samples (n = 3) were then 
stained with a first rabbit polyclonal antibody against 
collagen type I, collagen type IV, fibronectin or 
laminin (Abcam, Cambridge, UK). Then, sectioned 
samples were stained with a second goat anti-rabbit 
antibody labeled with Alexa Fluor® 594 (Abcam, 
Cambridge, UK). Lastly, the nuclear DNA was 
detected using with 4’, 6-diamidino-2-phenylindole 
dihydrochloride (DAPI) (Sigma-Aldrich, St. Louis, 
US). A fluorescence microscope (AXIO Observer A1, 
Zeiss, Oberkochen, Germany) was used to image the 
fluorescence-stained samples.  
Measurement of Young's modulus  
Young's modulus was measured as an indicative 
of stiffness in order to characterize 100% HepLL, 
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H/C=9/1, H/C=7/3, H/C=5/5, H/C=3/7, 
H/C=1/9, and 100% Caki-1 cells-laden hydrogels 
with a mass ratio of 2:3 of DLM/GelMA, in which the 
concentration of GelMA was 0.1 g/mL. The hydrogels 
were molded into a shape of cylinder with 
dimensions of 9 mm in height and 10 mm in diameter. 
The Young's modulus of the hydrogels was measured 
at a 1 mm/min rate under a mechanical tester 
(EFL-MT5600, Suzhou Intelligent Manufacturing 
Research Institute, Suzhou, China). 
Transduction of HepLL and Caki-1 cells 
A total number of 50,000 cells of HepLL and 
Caki-1 (a representative cell line derived from human 
kidney cancer, which has been commonly used to 
establish xenograft mouse renal cell carcinoma(RCC) 
models by subcapsular implantation [30, 31]) were 
added to a 24-well plate, and 500 μL of DMEM (Gibco, 
Melbourne, Australia) was added to each well. After 
24 hours, the pLenti-CMV-EGFP-3FLAG-PGK-Puro 
and pLenti-CMV-mCherry-3FLAG-PGK-Puro lenti-
virus (ObiO Technology, Shanghai, China) were 
added to HepLL and Caki-1 cells, respectively. After 
the virus was introduced to the cells for 12 hours, the 
medium was replaced. After 72 hours of virus 
introduction, the cells were observed under a 
microscope to confirm that the lentivirus were 
successfully transduced into the target cells. After a 
3-day puromycin (Sangon Biotech, Shanghai, China) 
treatment, the uninfected cells were removed. 
Preparation of microfluidic device for 
metastatic tumor progression model  
A microfluidic device, on which a metastatic 
tumor progression model was established, was 
assembled using poly (methyl methacrylate) (PMMA) 
for structural and spatial components. Poly 
(dimethylsiloxane) (PDMS), a hydrophobic elastomer 
with excellent gas permeability, was incorporated to 
facilitate gas exchange to the cells. The CorelDraw® 
system was used to design each layer of PMMA and a 
laser cutting machine (Universal Laser System, 
Scottsdale, US) was used to prepare the device 
containing an inlet and outlet as well as 7 microwells 
for 3D cell culture. For preparing the PDMS 
component, the precursor of PDMS and coagulant 
were mixed at a ratio of 10:1. After degassing for 30 
minutes, the mixture was then cured in a mold at 80 
°C for 1 hour. A PDMS sheet was obtained after 
peeling. A PET membrane with a pore size of 10 μm 
(GE Healthcare Life Science, Shanghai, China) was 
sliced to creating the required form-fitting shapes to 
be incorporated directly above the microwells. The 
3M Scotch-Weld adhesive was used in conjunction 
with screws to assemble the microfluidic device with 
multiple layers of PMMA and PDMS. 
Long-term cell culture in metastatic tumor 
progression model  
Prior to cell seeding, the assembled devices were 
initially sterilized with 75% ethanol over the course of 
24 hours and then sterilized with 2.5 μg/mL 
amphotericin integrated into 2% penicillin- 
streptomycin (Sangon Biotech, Shanghai, China) over 
a course of 2 hours. 
DMEM containing 10% fetal bovine serum (FBS) 
(Gibco, Melbourne, Australia) was subsequently used 
to suspend the HepLL and Caki-1 cells at varying 
ratios (100% HepLL, 9: 1 H/C, 7: 3 H/C, 5: 5 H/C, 3: 7 
H/C, 1: 9 H/C and 100% Caki-1 cells) with a final 
concentration of 1.0 × 107 cells per/mL. The cell 
suspension underwent 2 minutes of centrifugation at 
1,000 rpm and the same volume of 2:3 DLM/GelMA 
solution was used to replace the medium. The mixture 
was then transferred to the microfluidic device before 
exposure to ultraviolet (UV)-light for 30 seconds at a 
wavelength of 365 nm for solidification. DMEM was 
continuously flowed into the upper chamber of the 
microfluidic devices at a rate of 2 μL/h. For media 
perfusion and fluidic connection, silicone tubing (0.5 
mm ID × 2.0 mm OD, Longer Pump, Baoding, China) 
was used. 
On days 1, 7, and 14, Live/Dead assays (Dojindo, 
Kumamoto, Japan) were used to evaluate the cell 
viability as described by the manufacturer’s 
instructions. A Nikon A1 confocal fluorescence 
microscope (Nikon, Tokyo, Japan) was used to 
analyze the stained cells, and all images produced 
were analyzed with the ImageJ software. The 
percentage of live cells among all the seeded cells was 
used to evaluate cell viability. Furthermore, the 
transduced HepLL and Caki-1 cells were co-cultured 
for 7 days and then observed under a Nikon A1 
confocal fluorescence microscope to confirm the 
success of co-culture. 
Measurement of urea and albumin (ALB) 
secreted by liver cells 
The secretion of urea and ALB was quantified to 
assess hepatocyte function. The supernatant was 
collected from the co-culture on days 1, 7, and 14 with 
the DMEM media being replaced every 7 days. ELISA 
assay kits (Luding Biotechnology, Shanghai, China) 
were employed to quantify the level of secreted urea. 
ELISA assay kits (Gene beauty Technology, Wuhan, 
China) were also employed to quantify the level of 
secreted ALB, according to the manufacturers’ 
instructions. Measurements were taken with a 
SpectraMax M5 (Molecular Devices, San Jose, US) 
multifunctional microplate reader. 
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Efficacy measurement of 5-FU on metastatic 
tumor progression model 
Using the method described above, the HepLL 
and Caki-1 cells were homogenously combined into 
2:3 DLM/GelMA; it was then injected into the 
assembled devices to assess drug responses. The 
devices were incubated in 5% CO2 over the course of 
48 hours at 37 °C. All drug toxicity assessments were 
conducted through continuously exposing the HepLL 
and Caki-1 cells to media containing 0, 20.0, 40.0, and 
60.0 μg/ mL of 5-FU (MedChem Express, Monmouth 
Junction, NJ, USA) at a rate of 2 μL/h for 24 hours. 
Cell viability was determined using the CCK-8 kit 
(MedChem Express, Monmouth Junction, NJ, USA) 
with the absorbance being measured at a wavelength 
of 450 nm. 
Preparation of 5-FU-loaded PLGA-PEG NPs 
5-FU-loaded PLGA-PEG NPs were produced 
through the nanoprecipitation method [32]. Briefly, 10 
mg of 5-FU and 15 mg of PLGA (20 kDa) -PEG (5 kDa) 
polymer (Sigma-Aldrich, St. Louis, MO, USA) were 
first added into 1 mL of DMSO, as an organic phase, 
for thorough dissolving. Then, 1 mL of the organic 
mixture was added dropwisely into 10 mL of Milli-Q 
water at a rate of 0.2 mL/min via a syringe pump with 
constant magnetic stirring for 30 minutes. The 
obtained suspension was then passed through a 0.45 
µm pore size filter once and a 0.22 µm pore size filter 
twice to remove drug aggregates and to obtain NPs of 
the desired size and low polydispersity. The NP 
solution was then dialyzed via a dialysis membrane 
with a molecular weight cutoff of 12-14 kDa overnight 
to remove the remaining organic solvents from the 
solution. The NP solution was then collected and 
stored at 4 °C. 
Characterization of 5-FU-loaded PLGA-PEG 
NPs 
The size distribution of 5-FU-loaded PLGA-PEG 
NPs was measured using a dynamic light scattering 
(DLS) instrument (Zetasizer Nano S-90, Malvern, 
Worcestershire, UK) at ambient temperature. The 
angle of detection was set to 90°, and the wavelength 
of the helium/neon laser was 633 nm. The size of the 
NPs was determined according to the Stokes-Einstein 
equation.  
5-FU-loaded PLGA-PEG NPs were imaged with 
the aid of transmission electron microscopy (TEM) 
(Hitachi, Tokyo, Japan). A 2% (v/v) aqueous phos-
photungstic acid solution was used to negatively stain 
the NP suspension for 3 minutes. A drop (approxima-
tely 2 µL) of the stained NP suspension was added to 
a formvar-carbon coated copper electron microscopy 
grid. After drying, the stained samples were then 
imaged with TEM at 50,000× magnification. 
The encapsulation efficiency (EE) of 5-FU into 
NPs was determined using the following protocol. 
The 5-FU-loaded PLGA-PEG NP suspension was 
centrifuged (8,000 rpm, 10 min) briefly using an 
Amicon Ultra-0.5 centrifugal filter (10K cutoff), 
followed by resuspension of the NPs containing 
encapsulated 5-FU in ethanol (2 mL). A SpectraMax 
M5 multifunctional microplate reader was used to 
measure the concentration of the 5-FU in the mixture 
by obtaining the UV absorbance level of the above 
solution at 266 nm to calculate the drug mass in the 
PLGA-PEG. The EE was expressed as the percentage 
of encapsulated amount of drug (Edrug) in the total 
amount of drug used (Tdrug) as follows [33]: 
𝐸𝐸𝐸𝐸 (%) =  𝐸𝐸𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
𝑇𝑇𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
 ×  100% 
Delivery of Coumarin 6 by PLGA-PEG NPs  
Coumarin 6 (C6) (Sigma-Aldrich, St. Louis, MO, 
USA) -loaded PLGA-PEG NPs were primed as 
mentioned but by substituting 5-FU with C6 within 
the organic phase. HepLL and Caki-1 cells were 
placed into a 96-microwell plate with a cell density of 
6 × 104 cells/mL. After incubating for 24 hours, the 
medium was purged and refreshed with either 20 µL 
of the prepared C6-loaded PLGA-PEG NP solution or 
20 µL of C6 dissolved in water at a concentration 
corresponding to the C6 within the NP solution 
(determined through UV absorbance as described 
above). Cells were then incubated for an additional 24 
hours. Following incubation, cells were stained with 
DAPI as instructed by the manufacturer and imaged 
using a fluorescence microscope (Zeiss, Oberkochen, 
Germany) at a wavelength of 405 nm for DAPI 
staining and a wavelength of 505 nm for C6 imaging.  
Delivery of 5-FU by PLGA-PEG NPs in 
metastatic tumor progression model 
The HepLL and Caki-1 cells loaded into 2:3 
DLM/GelMA were flowed into the device. After 
UV-crosslinking, cells were incubated with 5% CO2 
over the course of 48 hours at 37 °C. The metastatic 
tumor progression model was continuously exposed 
to media encompassing 30.0 μg/mL of 5-FU or 
5-FU-loaded PLGA-PEG NPs for 24 hours. Finally, the 
cell viability within the hydrogels was analyzed using 
a Live/Dead kit and a Nikon A1 confocal fluorescence 
microscope. 
Statistical analysis 
Statistical analysis was performed using the 
one-way of variance (ANOVA) approach among the 
obtained data. The significance of the data was 
determined by a p value that was smaller than 0.05. 
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Results 
Characterization of biomimetic liver 
microenvironment 
The decellularized liver scaffold was obtained to 
create a biomimetic liver-specific ECM through a 
previously described protocol [29]. The rat livers 
gradually turned clear and transparent over the 
course of a 9-hour decellularization process (Figure 
2A). After H&E staining, evidence of pink 
eosinophilic staining denoted the presence of 
collagen, as opposed to the acellular nature being 
validated by the lack of basophilic hematoxylin 
staining (Figure 2B). SEM images also showed the 
acellular, mesh-like morphology of the decellularized 
matrices, while visible cells were observed in images 
of the native liver (Figure 2C). Furthermore, four 
major ECM proteins (i.e., collagen type I, collagen 
type IV, fibronectin and laminin) were identified 
(Figure 2D-G). Moreover, there was no detectable 
blue staining of nuclei by DAPI, indicating that the 
decellularization process was successful.  
 The mechanical properties of the 2:3 
DLM/GelMA hydrogels were characterized by 
gauging their Young's modulus as a biomechanical 
cue. The results demonstrated that the Young's 
modulus was 14.93 ± 1.10 kPa, 15.61 ± 1.69 kPa, 15.79 ± 
0.52 kPa, 14.37 ± 1.73 kPa, 15.41 ± 0.97 kPa, 15.31 ± 0.81 
kPa and 16.41 ± 0.92 kPa for the hydrogels with 100% 
HepLL, H/C=9/1, H/C=7/3, H/C=5/5, H/C=3/7, 
H/C=1/9, and 100% Caki-1, respectively (Figure 2H). 
These data indicated that Young's modulus of the 
hydrogel did not change significantly for the addition 
of different proportions of cells. Also, the Young's 
modulus of the 2:3 DLM/GelMA hydrogel was 
within the stiffness range of liver cancer 
(approximately 5 to 60 kPa) [34, 35]. 
Long-term 3D cell culture using the metastatic 
tumor progression model 
To observe the growth of HepLL and Caki-1 
cells, we transduced lentivirus into HepLL (MOI = 30) 
and Caki-1 (MOI = 20). As a result, HepLL cells 
expressed green fluorescent protein and Caki-1 cells 
expressed red fluorescent protein (Figure 3A-C). The 
ratio of green fluorescence on day 7 to day 1 were 1.25 
± 0.12, 1.12 ± 0.10, 1.03 ± 0.09, 1.17 ± 0.13, 1.05 ± 0.11 
and 1.08 ± 0.06 for 100% HepLL, H/C=9/1, H/C=7/3, 
H/C=5/5, H/C=3/7 and H/C=1/9, respectively. The 
ratio of red fluorescence on day 7 to day 1 were 1.28 ± 
0.16, 1.05 ± 0.10, 1.15 ± 0.12, 1.04 ± 0.08, 1.15 ± 0.07 and 
1.08 ± 0.07 for H/C=9/1, H/C=7/3, H/C=5/5, 
H/C=3/7, H/C=1/9 and 100% Caki-1, respectively. 
The above results indicated the relatively consistent 
increase of transduced HepLL and Caki-1 cells in the 
metastatic tumor progression model (Figure 3D-F).  
 
 
Figure 2. Characterization of the native liver, DLM, and Young’s modulus of DLM/GelMA hydrogel. (A) Gross images of a rat liver and DLM. (B) H&E staining of a native liver 
before and after decellularization. (C) SEM characterization of a native before and after decellularization. (D-G) Immuno-characterization of collagen I (red), collagen IV (red), 
fibronectin (red), and laminin (red) in the native liver and DLM. Nuclei of the cells were counterstained with DAPI (blue). (H) Measurement of Young’s modulus of 2:3 
DLM/GelMA hydrogel with varying cell ratios. Scale bar: 100 μm (B, D-G). (Avg. ± SD, NS indicates p > 0.05, n = 3). 
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Figure 3. Transduced HepLL and Caki-1 cells co-cultured in the tumor progression model based on metastasis-on-a-chip. (A) Transduction diagram demonstrating the 
introduction of Green fluorescent protein (GFP) and Red fluorescent protein (RFP). (B) 2D transduction results of HepLL expressing GFP and (C) Caki-1 cells expressing RFP. 
(D) Confocal images of HepLL and Caki-1 cells co-culture on the tumor progression model based on metastasis-on-a-chip on day 1 and day 7. The ratio of green (E) and red (F) 
fluorescence expressed on day 7 compared to day 1 (Avg. ± SD, n = 3). 
 
The cell viability of non-transduced HepLL and 
Caki-1 cells in DLM/GelMA scaffold was evaluated 
by live/dead staining. In the metastatic tumor 
progression model, where the cells were entirely 
embedded in 3D hydrogels in conjunction with 
continuous media perfusion, the HepLL and Caki-1 
cells were capable of culture for 14 days without a 
significant reduction in cell viability (Figure 4A). The 
cell viability values were 94.13 ± 1.20%, 94.23 ± 0.96%, 
94.03 ± 0.63%, 93.57 ± 2.16%, 93.16 ± 1.29% and 93.63 ± 
1.65% when evaluated on day 14. The viability of total 
cells within the scaffold at different ratios showed no 
significant difference (Figure 4B).  
Secretion of urea and ALB by liver cells 
The secretion level of urea and ALB from the 
HepLL cells over a 14-day culture period indicated 
the occurrence of metabolism and physiologically 
relevant cellular processes within the liver-specific 
ECM. Urea was consistently secreted from the 
non-transduced HepLL cells in the 2:3 DLM/GelMA 
hydrogels, indicated by the concentrations of 125.74 ± 
9.29 μM, 123 ± 6.10 μM and 130.58 ± 10.90 μM on days 
1, 7, and 14, respectively (Figure 4C). The urea 
concentration showed no significant difference over 
the duration of cell culture. In addition, the secretion 
of ALB showed a significant increase on day 7, and 
this level was maintained over the remaining culture 
period (5.98 ± 0.25 μg/mL, 7.33 ± 0.37 μg/mL, and 
7.08 ± 0.55 μg/mL on day 1, 7, and 14 respectively) 
(Figure 4D). The ALB concentration showed a 
significant difference on days 1 and 7, but showed no 
significant difference on days 7 and 14. 
Efficacy of 5-FU on metastatic tumor 
progression model 
The metastatic tumor progression model was 
used to assess the efficacy of 5-FU in killing Caki-1 
cells in liver-specific ECM. Cell viability was assessed 
over increasing concentrations of 5-FU (0, 20, 40, and 
60 μg/mL) in the different growth stages of the 
metastatic tumor progression model. The CCK-8 
assay results showed that the 5-FU treatment at 20, 40, 
and 60 μg/mL led to significant cell death after 24 
hours, as opposed to the untreated group, regardless 
of cell ratios (Figure 5A-G). Furthermore, the IC50 was 
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determined to be 54.56 ± 1.30 μg/mL, 43.01 ± 1.50 
μg/mL, 39.99 ± 1.51 μg/ mL, 34.87 ± 1.48 μg/mL, 
34.24 ± 1.63 μg/mL, 29.41 ± 0.87 μg/mL and 26.92 ± 
1.94 μg/mL in 100% HepLL, H/C=9/1, H/C=7/3, 
H/C=5/5, H/C=3/7, H/C=1/9 and 100% Caki-1, 
respectively. The IC50 decreased with increasing 
Caki-1 percentage, indicative of the linear anticancer 
relationship between 5-FU concentration and the 
percentage of Caki-1 cells in the co-culture system (R2 
= 0.89). The result showed that the more Caki-1 cells 
in the co-culture, the more cells were killed with the 
same dose of 5-FU, owing to HepLL cells being less 
sensitive to 5-FU (Figure 5H). 
Characterization of 5-FU-loaded PLGA-PEG 
NPs 
The PLGA-PEG polymer, as a model delivery 
system, was evaluated using our tumor progression 
model to increase the anti-cancer effects of 5-FU 
(Figure 6A). The resultant 5-FU-loaded PLGA-PEG 
NPs were characterized by DLS and TEM. DLS 
analysis showed the size distribution of 5-FU-loaded 
PLGA-PEG NPs from 50.7 to 190 nm, with an average 
size of 106.58 nm (Figure 6B). TEM images validated 
the formation of spherical NPs using the NP synthesis 
method as previously described (Figure 6B). In 
addition, the 5-FU EE (%) within the PLGA-PEG NPs 
was determined to be 35.46 ± 0.87%. 
 
 
Figure 4. Functional characterization of HepLL and Caki-1-laden DLM/GelMA hydrogels in the tumor progression model based on metastasis-on-a-chip. (A) Live/dead staining 
of HepLL and Caki-1 within 2.3 DLM/GelMA on days 1, 7, and 14 of cell culture. (B) Analysis of the cell viability on days 1, 7, and 14 (n = 3). (C-D) Measurements of ALB (C) and 
urea (D) secreted from the tumor progression model based on metastasis-on-a-chip. (Avg. ± SD, * stands for p < 0.05, NS indicates p > 0.05, n = 3). 
 
Figure 5. Cytotoxicity of 5-FU in the tumor progression model based on metastasis-on-a-chip. (A-G) Quantification of cytotoxicity of 5-FU for 100% HepLL, H/C=1/9, H/C=3/7, 
H/C=5/5, H/C=7/3, H/C=9/1 and 100% Caki-1, respectively, by a CCK-8 kit. (H) IC50 changes in different ratios of HepLL and Caki-1 cells. (Avg. ± SD, n = 3). 
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Figure 6. Characterization of 5-FU-loaded PLGA-PEG NPs and C6-loaded PLGA-PEG NPs co-cultured with HepLL and Caki-1 cells. (A) Schematic of NP-encapsulated 5-FU. (B) 
The size distribution and TEM of 5-FU-loaded PLGA-PEG NPs. Free C6 (C) and C6-loaded PLGA-PEG NPs (D) incubated with HepLL and Caki-1 cells for 24 h. (E) Comparison 
of fluorescence intensity of free C6 and C6-loaded PLGA-PEG NPs HepLL and Caki-1 cells. (Avg. ± SD, * stands for p < 0.05, n = 3). 
 
Delivery of C6 by PLGA-PEG NPs  
The delivery efficacy of C6 by PLGA-PEG NPs 
was evaluated by co-culture of free C6 and 
C6-PLGA-PEG NPs with the HepLL and Caki-1 cells, 
respectively. Fluorescence microscopic images 
showed a significantly higher cellular uptake of 
C6-loaded NPs versus the free C6 (Figure 6C-D). 
When incubated with free C6 and NP-encapsulated 
C6, the mean cell fluorescence of free C6 were 0.024 ± 
0.0011 and 0.025 ± 0.0017 for HepLL and Caki-1 cells, 
while the mean cell fluorescence of C6-PLGA-PEG 
NPs were 0.052 ± 0.0015 and 0.04 ± 0.0019, 
respectively. Both HepLL and Caki-1 cells had 
significantly higher normalized mean cell 
fluorescence (p < 0.05) when incubated with the 
C6-loaded NPs (Figure 6E), indicating that the NPs 
efficiently delivered C6 to the cells. 
Delivery of 5-FU by PLGA-PEG NPs in 
metastatic tumor progression model 
The delivery of 5-FU by PLGA-PEG NPs to the 
metastatic tumor progression model was confirmed 
by live/dead staining. Cell viability was measured 
over increasing concentrations of 5-FU and 30 μg/mL 
was chosen as the working concentration based on the 
IC50 results. The overlaid confocal images cells 
following live/dead staining illustrated that 5-FU and 
5-FU-loaded PLGA-PEG NP treatment at a 
concentration of 30 μg/mL resulted in significant (p < 
0.05) cell death after 24 hours, as opposed to the 
untreated group (Figure 7A). The cell viability was 
59.26 ± 4.57%, 55.52 ± 2.82%, 53.54 ± 2.11%, 50.53 ± 
2.47%, 48.49 ± 3.19%, 47.40 ± 3.04% and 45.54 ± 1.50% 
after 24 hours of co-culturing with 30 μg/mL of 5-FU 
at an increasing ratio of Caki-1 cells. Meanwhile, the 
cell viability was 51.75 ± 3.56%, 47.68 ± 4.09%, 45.46 ± 
2.32%, 41.09 ± 3.12%, 41.07 ± 3.11%, 44.27 ± 2.49% and 
39.53 ± 2.50% for 100% HepLL, H/C=9/1, H/C=7/3, 
H/C=5/5, H/C=3/7, H/C=1/9 and 100% Caki-1 cells 
after 24 hours of co-culture with 30 μg/mL of 
5-FU-loaded PLGA-PEG NPs, respectively. These 
results showed that 5-FU-loaded PLGA-PEG NPs 
were significantly more effective than free 5-FU in 
killing Caki-1 cells (p < 0.05) (Figure 7B-H). 
Discussion and conclusion 
Organ-specific ECM plays an important role in 
metastatic cancer; therefore, we simulated the 
biomimetic liver microenvironment in a tumor 
progression model based on metastasis-on-a-chip. In 
this study, we cultured Caki-1 cells in 3D biomimetic 
liver microenvironments (2:3 DLM/GelMA) to mimic 
the progression of metastatic kidney cancer in a 
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metastasis-on-a-chip model (Figure 1 and S1). The 
decellularized scaffold retains collagen I, collagen IV, 
fibronectin, and laminin (Figure 2), which are 
essential for tumor growth and metastasis [36-38]. As 
for biophysical cues, the Young's modulus obtained 
from the 2:3 DLM/GelMA (Figure 2H) is similar to 
that of a fibrotic liver (> 12 kPa) [39], and is within the 
liver stiffness range of liver cancer (approximately 5 to 
60 kPa) [34, 35]. In addition, a flow of fluid (2 μL/h) 
was implemented in the microfluidic system, not only 
providing the required shear stress to the cells, but 
also facilitating the exchange of oxygen and removal 
of metabolic waste. Through the construction of the 
organ-specific ECM, HepLL cells were able to 
continuously produce albumin and urea, mimicking 
the biological functions of liver. These results have 
suggested that DLM/GelMA-based biomimetic liver 
microtissues can mimic the organ-specific ECM for 
studying the progression of kidney cancer 
metastasized to the liver. 
 
 
Figure 7. Evaluation of 5-FU-loaded PLGA-PEG NPs’ toxicity using the metastatic tumor progression model. (A) Live/dead staining of HepLL and Caki-1 cells as well as the 
effects of 5-FU and 5-FU-loaded NPs on cell viability at 24 hours. (B-H) Cell viability of various ratios of HepLL to Caki-1 cells treated with 30 μg/mL of 5-FU or 5-FU-loaded NPs 
in the tumor progression model based on metastasis-on-a-chip at 24 hours. (Avg. ± SD, * stands for p < 0.05, n = 3). 
 
Figure 1. Schematic of the tumor progression model based on metastasis-on-a-chip. (A) Physiological representation of kidney cancer post-metastasis into the liver. (B) Diagram 
of the integration of co-culture by combining immortalized hepatocytes HepLL and kidney cancer Caki-1 cells into the ECM of 2:3 DLM/GelMA hydrogel. (C) Co-cultures of 
different ratios of HepLL to Caki-1 cells to mimic the progression of kidney cancer cells metastasized to the liver. (D) The efficacy of 5-FU, delivery of 5-FU though PLGA-PEG 
NPs, and dose optimization can be evaluated on the metastasis-on-a-chip platform. 
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To create tumor progression model based on 
metastasis-on-a-chip, we co-cultured different ratios 
of HepLL and Caki-1 cells in the organ-specific ECM. 
Transduced HepLL cells expressing green fluorescent 
protein and transduced Caki-1 cells expressing red 
fluorescent protein were successfully co-cultured with 
different cell ratios (Figure 3B-D). In addition, we 
used live/dead staining to assess long-term cell 
viability. To avoid fluorescence overlap in transduced 
cells, we used non-transduced cells to better study cell 
viability and function. The cell viability was greater 
than 90% at day 14, and HepLL cells continuously 
produced high levels of ALB and urea (Figure 4). 
Thus, this metastatic tumor progression model was 
used for long-term cell co-culture at an increasing 
ratio from 1:9 to 9:1 in a liver-specific ECM, and 
partial functions of hepatocytes were maintained. 
Although metastasis-on-a-chip models were used to 
study the migration of cancer cells and offer a feasible 
platform for drug testing [25, 27, 40], the progression 
of post-metastasis tumor within an organ-specific 
ECM has not been studied. Therefore, we mimic the 
post-metastasis progression through co-cultures of 
various ratios of HepLL and Caki-1 cells in a 
liver-specific ECM. 
The tumor progression model based on 
metastasis-on-a-chip can predict the therapeutic 
effects and evaluate the efficacy of anticancer drugs in 
inhibiting the growth of metastatic cancer cells. This 
metastatic tumor progression model showed the 
efficacy of 5-FU as well as a linear anticancer 
relationship between the concentration of 5-FU and 
the percentage of Caki-1 cells in the co-culture system 
(R2 = 0.89) (Figure 5). In addition, 5-FU-loaded 
PLGA-PEG NPs showed a stronger killing efficacy 
than free 5-FU at the same concentration (30 μg/mL) 
due to the delivery abilities of NPs (Figure 7), which is 
observed in a 2D model [33]. Compared to 
conventional 2D cultures and 3D Transwell, this 
bionic tumor progression model based on 
metastasis-on-a-chip with organ-specific ECM can 
better represent in vitro systems to study the efficacy 
of naked and carrier loaded drugs. On the other hand, 
unlike animal models, the tumor progression model 
based on metastasis-on-a-chip is less expensive, less 
labor intensive, and is not hindered by differences 
between animal and human cell responses. Therefore, 
the tumor progression model based on 
metastasis-on-a-chip can be used for accurate 
evaluation and prediction of the effects of drug 
treatment and drug delivery in an organ-specific 
ECM. 
Although the tumor progression model based on 
metastasis-on-a-chip is effective for drug evaluation, 
our study may suffer from the following limitations. 
First, we used the rat liver instead of the human liver 
in preparing ECM despite the disparity between 
Homo sapiens and Rodentia. Since DLM is commonly 
prepared by perfusing a series of detergents through 
the portal vein, it would be clinically challenging to 
collect whole human livers and to carry out the 
perfusion process for preparing human liver ECM 
[41]. Nevertheless, it has been shown that rat liver 
ECM has significant similarities with human liver 
ECM since both contain key growth factors and major 
collagens, which are key components in composing of 
biological and biomechanical cues in the liver [41, 42]. 
Second, it would be ideal to recapitulate the 
(pre)metastatic niche by using the liver ECM derived 
from a xenografted RCC model in our study. It has 
been previously reported that the primary tumor 
remodels the ECM in the metastatic sites distantly 
through soluble factors, exosomes and other 
microenvironmental cues for preparing the “soil” for 
“seeds”, i.e., circulating tumor cells to reside and grow 
[43, 44]. Since the (pre) metastatic niche clearly affects 
cell homing, colonization, adhesion, proliferation, and 
differentiation [45], it would be better to establish the 
(pre)metastatic ECM niche to a greater extent for 
studying metastasis and associated mechanisms. 
However, our research aims to establish a tumor 
progression model after the occurrence of metastasis 
for drug evaluation. As such, it is conceivable that the 
effect of using healthy liver ECM rather than 
(pre)metastatic ECM in our study would be less 
pronounced in causing bias for drug evaluation. 
Collectively, the use of healthy rat livers for preparing 
ECM, though not as ideal as human liver ECM or rat 
liver ECM derived from xenografted RCC, is more 
practical in preparing a post-metastasis tumor 
progression model on chip for preliminary drug 
evaluation. 
In summary, we developed a tumor progression 
model based on metastasis-on-a-chip that cultures 
kidney cancer cells in a 3D biomimetic liver ECM to 
mimic the progression of kidney cancer cells for 
predicting therapeutic effects and assessing dosage 
response at different stages of tumor progression. The 
novel tumor progression model is unique in terms of 
in vitro organ-specific ECM working in conjunction 
with the microfluidic system for providing biological 
biophysical, and biomechanical cues. Considering the 
technical challenge to establish a RCC model 
metastasized to the liver in rats via intrasplenic or 
intrahepatic injection, the post-metastatic tumor 
progression model is more cost-effective and practical 
to screen for therapeutic compounds, evaluate drug 
delivery routes, and assess treatment potency in 
preliminary studies. In addition, this tumor 
progression model can be adapted and potentially 
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used for developing personalized medicine for 
patients using patient-derived metastatic tumor 
tissues. Nevertheless, the translation of any key 
findings from tumor-on-a-chip platforms to clinical 
usage would require stringent validation through 
animal studies and clinical trials. 
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